Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.22%||69.65||1.0%||$510.30m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.08%||205.22||1.9%||$451.66m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.61%||635.09||2.7%||$406.05m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.38%||4.31||0.7%||$301.28m|
|EXAS||EXACT Sciences Corp.||3.12%||83.36||18.0%||$145.51m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.23%||86.12||4.2%||$137.03m|
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.